MSD Korea's antibiotic drug Zerbaxa has been recognized for its benefit adequacy by the HIRA Drug Reimbursment Evaluation Committee. As a result, it is likely to be listed on health insurance benefits through NHIS negotiations.

The HIRA released the results of the 6th Drug Reimbursment Evaluation Committee review on the 2nd, and determined that Zerbaxa was appropriate for complex intra-abdominal infection, complex urinary tract infection, and hospital infection pneumonia.

Zerbaxa is a super antibiotic approved in Korea in 2017, and is evaluated as a drug that can overcome antibiotic resistance. Dr. Low, who has challenged since 2018, succeeded in passing the Drug Reimbursment Evaluation